prostate cancer treatment Follow

Altor BioScience Corporation announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase II Bridge Grant by the National Cancer Institute (NCI). The award of $3 MM over three years will help Altor further its clinical development[...]

Reuters - Doctors caring for patients with early stage prostate cancer may do better to watch and wait to see if tumors develop rather than engage in aggressive treatment that may do no good, scientis ...

(3 stars) Story implies that hormone therapy is one size fits all. In fact this study was about different risks from different hormone therapies. Story also missed key points about the study design.

NEW YORK (Reuters Health) – Particle beam radiation has been available since 1954, but a systematic literature review has failed to turn up statistically or clinically significant differences in survival or in serious adverse events with this treatment[...]

NEW YORK (Reuters Health) – New research indicates that over half of men who choose watchful waiting as the initial strategy for prostate cancer require no treatment on long-term follow-up. “Patients and doctors should not assume that any/all cancer[...]